Prevalence of NAFLD, MAFLD and associated advanced fibrosis in the contemporary United States population
Prevalence of NAFLD, MAFLD and associated advanced fibrosis in the contemporary United States population
复制标题
DOI：
10.1111/liv.14828
复制
发表时间：
2021-03-03
影响因子：
6.7
通讯作者：
Perseghin, Gianluca
中科院分区：
文献类型：
--
作者：
Ciardullo, Stefano;Perseghin, Gianluca
关于最近术语从非酒精性脂肪肝（NAFLD）到代谢功能障碍相关脂肪肝（MAFLD）的变化的流行病学意义的数据有限。因此，我们对2017-2018年国家健康和营养检查调查中招募的成年人进行了横断面研究，这是美国普通人群的代表性样本。基于通过振动控制瞬态弹性成像（VCTE）获得的受控衰减参数（CAP）和肝脏硬度测量（LSM），NAFLD和MAFLD的患病率分别为37.1%（95%CI 34.0-40.4）和39.1%（95%CI 36.3-42.1），西班牙裔个体的患病率更高。这两个定义之间的一致性很高（科恩的kappa 0.92）。NAFLD和MAFLD患者的晚期肝纤维化风险也相似（分别为7.5%和7.4%）。我们的研究结果表明，最近诊断标准的变化并没有影响美国普通人群中该病的患病率。
Data are limited on the epidemiological implications of the recent change in terminology from nonalcoholic fatty liver disease (NAFLD) to metabolic dysfunction-associated fatty liver disease (MAFLD). We therefore performed a cross-sectional study of adults recruited in the 2017-2018 National Health and Nutrition Examination Survey, a representative sample of the general US population. The prevalence of NAFLD and MAFLD based on controlled attenuation parameter (CAP) and liver stiffness measurement (LSM) obtained through vibration-controlled transient elastography (VCTE) were 37.1% (95% CI 34.0-40.4) and 39.1% (95% CI 36.3-42.1), respectively, with higher rates among Hispanic individuals. Agreement between the two definitions was high (Cohen's kappa 0.92). Patients with NAFLD and MAFLD also showed similar risk of advanced liver fibrosis (7.5% and 7.4% respectively). Our results suggest that the recent change in diagnostic criteria did not affect the prevalence of the condition in the general United States population.